Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism

A clinical review

Vincent A. Pallazola, Rishi K. Kapoor, Karan Kapoor, John W. McEvoy, Roger S Blumenthal, Ty J. Gluckman

Research output: Contribution to journalReview article

Abstract

Non-valvular atrial fibrillation and venous thromboembolism anticoagulation risk assessment tools have been increasingly utilized to guide implementation and duration of anticoagulant therapy. Anticoagulation significantly reduces stroke and recurrent venous thromboembolism risk, but comes at the cost of increased risk of major and clinically relevant non-major bleeding. The decision for anticoagulation in high-risk patients is complicated by the fact that many risk factors associated with increased thromboembolic risk are simultaneously associated with increased bleeding risk. Traditional risk assessment tools rely heavily on age, sex, and presence of cardiovascular comorbidities, with newer tools additionally taking into account changes in risk factors over time and novel biomarkers to facilitate more personalized risk assessment. These tools may help counsel and inform patients about the risks and benefits of starting or continuing anticoagulant therapy and can identify patients who may benefit from more careful management. Although the ability to predict anticoagulant-associated hemorrhagic risk is modest, ischemic and bleeding risk scores have been shown to add significant value to therapeutic management decisions. Ultimately, further work is needed to optimally implement accurate and actionable risk stratification into clinical practice.

Original languageEnglish (US)
JournalVascular Medicine (United Kingdom)
DOIs
StatePublished - Jan 1 2019

Fingerprint

Venous Thromboembolism
Atrial Fibrillation
Anticoagulants
Hemorrhage
Comorbidity
Therapeutics
Biomarkers
Stroke

Keywords

  • anticoagulation
  • atrial fibrillation
  • bleeding
  • risk stratification
  • stroke
  • venous thromboembolism (VTE)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism : A clinical review. / Pallazola, Vincent A.; Kapoor, Rishi K.; Kapoor, Karan; McEvoy, John W.; Blumenthal, Roger S; Gluckman, Ty J.

In: Vascular Medicine (United Kingdom), 01.01.2019.

Research output: Contribution to journalReview article

@article{4b92702772e34e3c8d8e18fd08490d75,
title = "Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review",
abstract = "Non-valvular atrial fibrillation and venous thromboembolism anticoagulation risk assessment tools have been increasingly utilized to guide implementation and duration of anticoagulant therapy. Anticoagulation significantly reduces stroke and recurrent venous thromboembolism risk, but comes at the cost of increased risk of major and clinically relevant non-major bleeding. The decision for anticoagulation in high-risk patients is complicated by the fact that many risk factors associated with increased thromboembolic risk are simultaneously associated with increased bleeding risk. Traditional risk assessment tools rely heavily on age, sex, and presence of cardiovascular comorbidities, with newer tools additionally taking into account changes in risk factors over time and novel biomarkers to facilitate more personalized risk assessment. These tools may help counsel and inform patients about the risks and benefits of starting or continuing anticoagulant therapy and can identify patients who may benefit from more careful management. Although the ability to predict anticoagulant-associated hemorrhagic risk is modest, ischemic and bleeding risk scores have been shown to add significant value to therapeutic management decisions. Ultimately, further work is needed to optimally implement accurate and actionable risk stratification into clinical practice.",
keywords = "anticoagulation, atrial fibrillation, bleeding, risk stratification, stroke, venous thromboembolism (VTE)",
author = "Pallazola, {Vincent A.} and Kapoor, {Rishi K.} and Karan Kapoor and McEvoy, {John W.} and Blumenthal, {Roger S} and Gluckman, {Ty J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1358863X18819816",
language = "English (US)",
journal = "Vascular Medicine",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism

T2 - A clinical review

AU - Pallazola, Vincent A.

AU - Kapoor, Rishi K.

AU - Kapoor, Karan

AU - McEvoy, John W.

AU - Blumenthal, Roger S

AU - Gluckman, Ty J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Non-valvular atrial fibrillation and venous thromboembolism anticoagulation risk assessment tools have been increasingly utilized to guide implementation and duration of anticoagulant therapy. Anticoagulation significantly reduces stroke and recurrent venous thromboembolism risk, but comes at the cost of increased risk of major and clinically relevant non-major bleeding. The decision for anticoagulation in high-risk patients is complicated by the fact that many risk factors associated with increased thromboembolic risk are simultaneously associated with increased bleeding risk. Traditional risk assessment tools rely heavily on age, sex, and presence of cardiovascular comorbidities, with newer tools additionally taking into account changes in risk factors over time and novel biomarkers to facilitate more personalized risk assessment. These tools may help counsel and inform patients about the risks and benefits of starting or continuing anticoagulant therapy and can identify patients who may benefit from more careful management. Although the ability to predict anticoagulant-associated hemorrhagic risk is modest, ischemic and bleeding risk scores have been shown to add significant value to therapeutic management decisions. Ultimately, further work is needed to optimally implement accurate and actionable risk stratification into clinical practice.

AB - Non-valvular atrial fibrillation and venous thromboembolism anticoagulation risk assessment tools have been increasingly utilized to guide implementation and duration of anticoagulant therapy. Anticoagulation significantly reduces stroke and recurrent venous thromboembolism risk, but comes at the cost of increased risk of major and clinically relevant non-major bleeding. The decision for anticoagulation in high-risk patients is complicated by the fact that many risk factors associated with increased thromboembolic risk are simultaneously associated with increased bleeding risk. Traditional risk assessment tools rely heavily on age, sex, and presence of cardiovascular comorbidities, with newer tools additionally taking into account changes in risk factors over time and novel biomarkers to facilitate more personalized risk assessment. These tools may help counsel and inform patients about the risks and benefits of starting or continuing anticoagulant therapy and can identify patients who may benefit from more careful management. Although the ability to predict anticoagulant-associated hemorrhagic risk is modest, ischemic and bleeding risk scores have been shown to add significant value to therapeutic management decisions. Ultimately, further work is needed to optimally implement accurate and actionable risk stratification into clinical practice.

KW - anticoagulation

KW - atrial fibrillation

KW - bleeding

KW - risk stratification

KW - stroke

KW - venous thromboembolism (VTE)

UR - http://www.scopus.com/inward/record.url?scp=85061753465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061753465&partnerID=8YFLogxK

U2 - 10.1177/1358863X18819816

DO - 10.1177/1358863X18819816

M3 - Review article

JO - Vascular Medicine

JF - Vascular Medicine

SN - 1358-863X

ER -